Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study-Reference-Cited by-同舟云学术

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study

Published:2015-12 Issue:12 Volume:2 Page:e516-e527
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Richardson Paul G,Jagannath Sundar,Moreau Philippe,Jakubowiak Andrzej J,Raab Marc S,Facon Thierry,Vij Ravi,White Darrell,Reece Donna E,Benboubker Lotfi,Zonder Jeffrey,Tsao L Claire,Anderson Kenneth C,Bleickardt Eric,Singhal Anil K,Lonial Sagar

Publisher

Elsevier BV

Subject

Hematology

Reference40 articles.

1. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu;Tai;Blood,2008

2. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma;Hsi;Clin Cancer Res,2008

3. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Harousseau;Ann Oncol,2010

4. Salvage therapy of multiple myeloma: the new generation drugs;Romano;Biomed Res Int,2014

5. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis;Pozzi;Br J Haematol,2013

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review: Mechanisms and molecular pathways of signaling lymphocytic activation molecule family 3 (SLAMF3) in immune modulation and therapeutic prospects;International Immunopharmacology;2024-05

2. Disseminated Nontuberculous Mycobacterium Infection During Treatment of Multiple Myeloma: A Case Report and Review of the Literature;Internal Medicine;2024

3. Ex-vivo CS1-OKT3 dual specific bivalent antibody-armed effector T cells mediate cellular immunity against multiple myeloma;Scientific Reports;2023-11-27

4. Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment;Cell Reports Medicine;2023-10

5. CAR-T Therapy in Relapsed Refractory Multiple Myeloma;Current Medicinal Chemistry;2023-09-27